STM: Successful human trial against colon cancer virus
Oncolytics Biotech Inc. recently published a paper in the latest issue of the Journal of Scientific Translation (4 volume 387 issue 138ra77). The paper reports the results from the UK Translational Clinical Trial (REO 013). In this experiment, REOLYSIN was intravenously administered to patients with colorectal cancer who had not had liver metastases removed. The first author of the paper was co-signed by two scientists from the Leeds Institute of Molecular Medicine in the United Kingdom and the London Cancer Institute.
The experiment is a non-blind, non-random, single-center study. For patients with colorectal cancer, REOLYSIN is given intravenously for 5 consecutive days before surgical removal of liver metastases. Ten patients received REOLYSIN intravenously 1x1010 TCID50 1-4 weeks before surgery. After surgery, cancer tissue and adjacent liver tissue are used to assess the status of the virus and its anti-tumor effect.
Studies have shown that even though all patients receiving treatment have been immunized against the virus, the virus can still specifically target liver metastases in 90% of patients. Researchers have shown that this retrovirus can combine with special blood cells to evade immune neutralization, thereby transmitting the virus to the tumor. Analysis of surgical samples showed that the expression of retroviral proteins was more pronounced in malignant tumor cells than tumor stromal or surrounding normal liver tissue. Fresh tissue from 4 patients is available, and in all these samples, there is evidence that a virus factory exists in the tumor tissue, and the virus restores its replication ability in the tumor, but not in normal liver tissue. The researchers demonstrated for the first time that when intravenously injecting a patient with an oncolytic virus, the virus can hide itself by carrying blood cells to escape the role of neutralizing antibodies, thereby specifically targeting tumor tissue.
"These findings are very important. They give us a deeper understanding of how REOLYSIN interacts with the human immune system and how to maintain its cytotoxicity after intravenous injection." Oncolytics' President and CEO said. "It also draws our attention to the ability of retroviruses to target cancer cells and to make virus factories in tumor tissue without harming normal tissue."
"We believe this trial is a critical step towards viral treatment," said Dr. Alan Melcher, professor of cancer and biotherapy at the University of Leeds, UK. "It demonstrates for the first time that intravenous injection of patients with retroviruses can selectively target cancer cells, replicate in them, and kill tumor cells with little effect on normal tissues. It also shows that even if there is antivirus in the blood Antibodies, viruses can still "ride" blood cells to avoid immune neutralization and reach cancer cells. "
The experiment is a non-blind, non-random, single-center study. For patients with colorectal cancer, REOLYSIN is given intravenously for 5 consecutive days before surgical removal of liver metastases. Ten patients received REOLYSIN intravenously 1x1010 TCID50 1-4 weeks before surgery. After surgery, cancer tissue and adjacent liver tissue are used to assess the status of the virus and its anti-tumor effect.
Studies have shown that even though all patients receiving treatment have been immunized against the virus, the virus can still specifically target liver metastases in 90% of patients. Researchers have shown that this retrovirus can combine with special blood cells to evade immune neutralization, thereby transmitting the virus to the tumor. Analysis of surgical samples showed that the expression of retroviral proteins was more pronounced in malignant tumor cells than tumor stromal or surrounding normal liver tissue. Fresh tissue from 4 patients is available, and in all these samples, there is evidence that a virus factory exists in the tumor tissue, and the virus restores its replication ability in the tumor, but not in normal liver tissue. The researchers demonstrated for the first time that when intravenously injecting a patient with an oncolytic virus, the virus can hide itself by carrying blood cells to escape the role of neutralizing antibodies, thereby specifically targeting tumor tissue.
"These findings are very important. They give us a deeper understanding of how REOLYSIN interacts with the human immune system and how to maintain its cytotoxicity after intravenous injection." Oncolytics' President and CEO said. "It also draws our attention to the ability of retroviruses to target cancer cells and to make virus factories in tumor tissue without harming normal tissue."
"We believe this trial is a critical step towards viral treatment," said Dr. Alan Melcher, professor of cancer and biotherapy at the University of Leeds, UK. "It demonstrates for the first time that intravenous injection of patients with retroviruses can selectively target cancer cells, replicate in them, and kill tumor cells with little effect on normal tissues. It also shows that even if there is antivirus in the blood Antibodies, viruses can still "ride" blood cells to avoid immune neutralization and reach cancer cells. "
Chamomile Oil,Pure Essential Oil Set,Orange Oil,Pure Spearmint Oil
Ji'An ZhongXiang Natural Plants Co.,Ltd. , https://www.jxzxessentialoils.com